VERTEX PHARMACEUTICALS INC / MA Share-based Payment Arrangement, Expense, Tax Benefit
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Share-based Payment Arrangement, Expense, Tax Benefit of $35.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Income Tax
us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, expense, tax benefit for the quarter ending 2026-06-30 was $35.30M, a 3.29% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, expense, tax benefit for the quarter ending 2026-03-31 was $35.30M, a 53.06% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, expense, tax benefit for the quarter ending 2025-12-31 was -$30.60M, a 212.09% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, expense, tax benefit for the quarter ending 2025-09-30 was $47.50M, a 26.47% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, expense, tax benefit for fiscal 2025 was $128.60M, a 48.89% decline from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, expense, tax benefit for fiscal 2024 was $251.60M, a 50.21% increase from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, expense, tax benefit for fiscal 2023 was $167.50M, a 16.24% increase from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, expense, tax benefit for fiscal 2022 was $144.10M, a 73.82% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense, Tax Benefit 3 month | Share-based Payment Arrangement, Expense, Tax Benefit 3 month as first filed | Share-based Payment Arrangement, Expense, Tax Benefit 6 month | Share-based Payment Arrangement, Expense, Tax Benefit 6 month as first filed | Share-based Payment Arrangement, Expense, Tax Benefit 9 month | Share-based Payment Arrangement, Expense, Tax Benefit 9 month as first filed | Share-based Payment Arrangement, Expense, Tax Benefit 12 month | Share-based Payment Arrangement, Expense, Tax Benefit 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $35.30M 10-Q · filed 2026-08-04 | $70.60M 10-Q · filed 2026-08-04 | $40.00M derived: sum of 3 quarters · filed 2026-08-04 | $87.50M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $35.30M 10-Q · filed 2026-05-05 | $4.70M derived: sum of 2 quarters · filed 2026-05-05 | $52.20M derived: sum of 3 quarters · filed 2026-05-05 | $88.70M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | -$30.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $16.90M derived: sum of 2 quarters · filed 2026-02-13 | $53.40M derived: sum of 3 quarters · filed 2026-08-04 | $128.60M 10-K · filed 2026-02-13 | ||||
| 2025-09-30 | $47.50M 10-Q · filed 2025-11-04 | $84.00M derived: sum of 2 quarters · filed 2026-08-04 | $159.20M 10-Q · filed 2025-11-04 | $186.50M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $36.50M 10-Q · filed 2026-08-04 | $111.70M 10-Q · filed 2026-08-04 | $139.00M derived: sum of 3 quarters · filed 2026-08-04 | $203.60M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $75.20M 10-Q · filed 2026-05-05 | $102.50M derived: sum of 2 quarters · filed 2026-05-05 | $167.10M derived: sum of 3 quarters · filed 2026-05-05 | $247.80M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $27.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $91.90M derived: sum of 2 quarters · filed 2026-02-13 | $172.60M derived: sum of 3 quarters · filed 2026-02-13 | $251.60M 10-K · filed 2026-02-13 | ||||
| 2024-09-30 | $64.60M 10-Q · filed 2025-11-04 | $145.30M derived: sum of 2 quarters · filed 2025-11-04 | $224.30M 10-Q · filed 2025-11-04 | $282.80M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-06-30 | $80.70M 10-Q · filed 2025-08-05 | $159.70M 10-Q · filed 2025-08-05 | $218.20M derived: sum of 3 quarters · filed 2026-02-13 | $255.30M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-03-31 | $79.00M 10-Q · filed 2025-05-06 | $137.50M derived: sum of 2 quarters · filed 2026-02-13 | $174.60M derived: sum of 3 quarters · filed 2026-02-13 | $205.90M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2023-12-31 | $58.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $95.60M derived: sum of 2 quarters · filed 2026-02-13 | $126.90M derived: sum of 3 quarters · filed 2026-02-13 | $167.50M 10-K · filed 2026-02-13 | ||||
| 2023-09-30 | $37.10M 10-Q · filed 2024-11-05 | $68.40M derived: sum of 2 quarters · filed 2024-11-05 | $109.00M 10-Q · filed 2024-11-05 | $151.80M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-06-30 | $31.30M 10-Q · filed 2024-08-02 | $71.90M 10-Q · filed 2024-08-02 | $114.70M derived: sum of 3 quarters · filed 2025-02-13 | $153.50M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-03-31 | $40.60M 10-Q · filed 2024-05-07 | $83.40M derived: sum of 2 quarters · filed 2025-02-13 | $122.20M derived: sum of 3 quarters · filed 2025-02-13 | $148.70M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2022-12-31 | $42.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $81.60M derived: sum of 2 quarters · filed 2025-02-13 | $108.10M derived: sum of 3 quarters · filed 2025-02-13 | $144.10M 10-K · filed 2025-02-13 | ||||
| 2022-09-30 | $38.80M 10-Q · filed 2023-11-07 | $65.30M derived: sum of 2 quarters · filed 2023-11-07 | $101.30M 10-Q · filed 2023-11-07 | $110.50M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | $26.50M 10-Q · filed 2023-08-02 | $62.50M 10-Q · filed 2023-08-02 | $71.70M derived: sum of 3 quarters · filed 2024-02-15 | $93.30M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | $36.00M 10-Q · filed 2023-05-02 | $45.20M derived: sum of 2 quarters · filed 2024-02-15 | $66.80M derived: sum of 3 quarters · filed 2024-02-15 | $87.70M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | $9.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $30.80M derived: sum of 2 quarters · filed 2024-02-15 | $51.70M derived: sum of 3 quarters · filed 2024-02-15 | $82.90M 10-K · filed 2024-02-15 | ||||
| 2021-09-30 | $21.60M 10-Q · filed 2022-10-28 | $21.56M 10-Q · filed 2021-11-03 | $42.50M derived: sum of 2 quarters · filed 2022-10-28 | $73.70M 10-Q · filed 2022-10-28 | $73.66M 10-Q · filed 2021-11-03 | $90.11M derived: sum of 4 quarters · filed 2023-02-10 | ||
| 2021-06-30 | $20.90M 10-Q · filed 2022-08-05 | $20.86M 10-Q · filed 2021-07-30 | $52.10M 10-Q · filed 2022-08-05 | $52.11M 10-Q · filed 2021-07-30 | $68.51M derived: sum of 3 quarters · filed 2023-02-10 | $103.80M derived: sum of 4 quarters · filed 2023-02-10 | ||
| 2021-03-31 | $31.30M 10-Q · filed 2022-05-06 | $31.25M 10-Q · filed 2021-04-30 | $47.61M derived: sum of 2 quarters · filed 2023-02-10 | $82.90M derived: sum of 3 quarters · filed 2023-02-10 | $114.05M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2020-12-31 | $16.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $51.60M derived: sum of 2 quarters · filed 2023-02-10 | $82.75M derived: sum of 3 quarters · filed 2023-02-10 | $147.00M 10-K · filed 2023-02-10 | $146.96M 10-K · filed 2021-02-11 | |||
| 2020-09-30 | $35.30M 10-Q · filed 2021-11-03 | $66.45M derived: sum of 2 quarters · filed 2021-11-03 | $130.69M 10-Q · filed 2021-11-03 | $167.25M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-06-30 | $31.15M 10-Q · filed 2021-07-30 | $95.40M 10-Q · filed 2021-07-30 | $131.96M derived: sum of 3 quarters · filed 2022-02-09 | $153.96M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-03-31 | $64.25M 10-Q · filed 2021-04-30 | $100.81M derived: sum of 2 quarters · filed 2022-02-09 | $122.80M derived: sum of 3 quarters · filed 2022-02-09 | $148.92M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2019-12-31 | $36.56M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $58.56M derived: sum of 2 quarters · filed 2022-02-09 | $84.68M derived: sum of 3 quarters · filed 2022-02-09 | $124.20M 10-K · filed 2022-02-09 | $124.22M 10-K · filed 2020-02-13 | |||
| 2019-09-30 | $22.00M 10-Q · filed 2020-10-30 | $48.11M derived: sum of 2 quarters · filed 2020-10-30 | $87.64M 10-Q · filed 2020-10-30 | $73.92M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $26.12M 10-Q · filed 2020-07-31 | $65.64M 10-Q · filed 2020-07-31 | $51.93M derived: sum of 3 quarters · filed 2021-02-11 | $48.81M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-03-31 | $39.52M 10-Q · filed 2020-05-01 | $25.81M derived: sum of 2 quarters · filed 2021-02-11 | $22.70M derived: sum of 3 quarters · filed 2021-02-11 | $17.66M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2018-12-31 | -$13.71M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | -$16.83M derived: sum of 2 quarters · filed 2021-02-11 | -$21.86M derived: sum of 3 quarters · filed 2021-02-11 | $0.00 10-K · filed 2021-02-11 | ||||
| 2018-09-30 | -$3.11M 10-Q · filed 2019-10-31 | -$8.14M derived: sum of 2 quarters · filed 2019-10-31 | $13.71M 10-Q · filed 2019-10-31 | |||||
| 2018-06-30 | -$5.03M 10-Q · filed 2019-08-01 | $16.83M 10-Q · filed 2019-08-01 | ||||||
| 2018-03-31 | $21.86M 10-Q · filed 2019-05-01 | |||||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |